Abdominal Pain Clinical Trial
Official title:
A Randomized Controlled Trial of a Commercially-Available Probiotic Supplement (Trenev Trio®/Healthy Trinity®) and the Promotion of Normal Gastrointestinal Function Among Adults With Recurrent Gastrointestinal Symptoms
Verified date | September 2021 |
Source | University of Maryland, Baltimore |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Participants experiencing recurrent gastrointestinal symptoms in this double-blind, randomized, controlled trial will receive either a commercially-available probiotic dietary supplement or placebo. The investigators hypothesize that participants in the probiotic dietary supplement group will experience greater improvement in their gastrointestinal symptoms than participants in the placebo group.
Status | Completed |
Enrollment | 80 |
Est. completion date | October 2015 |
Est. primary completion date | September 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Self-reported response of "moderate discomfort" or worse (3 or greater on 1-5 Likert Scale) and "frequent discomfort" or more often (3 or greater on 1-5 Likert scale) from at least 2 of the following gastrointestinal symptoms: gas, indigestion, bloating, abdominal pain, or defecation irregularity as expressed on Likert scale (1=very minor or no discomfort, 2=minor discomfort, 3=moderate discomfort, 4=high discomfort, 5=very high discomfort) over the previous 3 weeks 2. Agree to continue with typical diet and exercise habits during study 3. Agree to use contraception or abstinence throughout study period, unless postmenopausal or surgically sterile (females only) 4. Able to understand and voluntarily consent to the study and understand its nature and purpose including potential risks and side effects Exclusion Criteria: 1. Current and documented diagnosis of Inflammatory Bowel Disease (Crohn's disease or ulcerative colitis), Celiac disease, active peptic ulcer, active diverticulitis, and other active cases of gastrointestinal diseases that, in the investigators' opinions, may affect participant safety. 2. Current and documented diagnosis of any other non-gastrointestinal disease that, in the investigators' opinions, may affect participant safety or confound the evaluation of the study outcomes. Excluded conditions include congestive heart failure, malignancy, uncontrolled diabetes mellitus, uncontrolled autoimmune disease (lupus, rheumatoid arthritis, eczema), eating disorders, and any other active health condition or disease that the investigators feel contradict the intended study population of participants in good health. 3. Daily consumption of another probiotic supplement or new consumption of fermented dairy products (yogurt, kefir, etc.) 4. Usage of systemic steroids during the past 2 months 5. Usage of antipsychotic medications during the past 2 months 6. Usage of prednisone, 6-mercaptopurine, adalimumab, etanercept, infliximab, leflunomide, golimumab, or mycophenolate mofetil during the past 2 months 7. Uncontrolled anxiety or current medication for anxiety disorder 8. Pregnant or breastfeeding females 9. History of alcohol, drug, or medication abuse 10. Known allergies to any substance in the study product 11. Previous major gastrointestinal tract surgery (colon resection, gastric bypass, etc.) 12. Participation in another clinical trial within 30 days of screening |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Maryland, Baltimore |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Gastrointestinal Symptom Rating Scale | Study end (6 weeks from baseline) | ||
Other | Gastrointestinal Quality of Life Index | Study end (6 weeks from baseline) | ||
Other | Bristol Stool Scale | Study end (6 weeks from baseline) | ||
Other | Rescue medication usage | Study end (6 weeks from baseline) | ||
Other | Adequate relief | "In the past 7 days, have you had adequate relief of your gastrointestinal discomfort?" | Study end (6 weeks from baseline) | |
Primary | Severity of self-reported bloating | Likert scale | Study end (6 weeks from baseline) | |
Primary | Severity of self-reported gas | Likert scale | Study end (6 weeks from baseline) | |
Primary | Severity of self-reported indigestion | Likert scale | Study end (6 weeks from baseline) | |
Primary | Severity of self-reported abdominal pain | Likert scale | Study end (6 weeks from baseline) | |
Primary | Severity of self-reported defecation irregularity | Likert scale | Study end (6 weeks from baseline) | |
Secondary | Frequency of self-reported bloating | Likert scale | Study end (6 weeks from baseline) | |
Secondary | Frequency of self-reported gas | Likert scale | Study end (6 weeks from baseline) | |
Secondary | Frequency of self-reported indigestion | Likert scale | Study end (6 weeks from baseline) | |
Secondary | Frequency of self-reported abdominal pain | Likert scale | Study end (6 weeks from baseline) | |
Secondary | Frequency of self-reported defecation irregularity | Likert scale | Study end (6 weeks from baseline) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04682860 -
Management of Abdominal Pain in Acute Gastroenteritis Patients With Hyoscine Butylbromide
|
Phase 4 | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 | |
Completed |
NCT02547857 -
Transvaginal Pelvic Ultrasound in the ED
|
N/A | |
Completed |
NCT02923245 -
POCUS Assessment of Bladder Fullness for Girls Awaiting Radiology-Performed Transabdominal Pelvic Ultrasound
|
N/A | |
Completed |
NCT02676232 -
DARWeb: an Online Psychosocial Intervention for Children With Recurrent Abdominal Pain and Their Families.
|
N/A | |
Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
Recruiting |
NCT00209807 -
Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder
|
Phase 4 | |
Terminated |
NCT01410071 -
Evaluation of Gastrointestinal Symptoms and Quality of Life in Patients With Sphincter of Oddi Dysfunction
|
N/A | |
Terminated |
NCT01736280 -
Evaluating and Treating Potential Research Participants With Digestive Disorders
|
N/A | |
Enrolling by invitation |
NCT04104867 -
Effectiveness of Prokinetic Agents in Improving Abdominal Discomfort at Colonoscopy
|
N/A | |
Completed |
NCT03574727 -
Abdominal Cutaneous Nerve Entrapment Syndrome
|
||
Completed |
NCT04614649 -
Right Iliac Fossa Treatment-Turkey Audit
|
||
Completed |
NCT05438654 -
Improvement of Diagnostic Approach Using PoCUS for Right Upper Quadrant Abdominal Pain
|
N/A | |
Completed |
NCT06423586 -
Effect of Lecithin-based Curcuma and Boswellia on Post-acute COVID-19 IBS
|
N/A | |
Completed |
NCT03558009 -
Epidemiological Analysis for Hereditary Angioedema Disease
|
||
Terminated |
NCT03148288 -
Vitamin D Supplementation in IBS
|
N/A | |
Completed |
NCT03708874 -
Pain Management of Emergency Laparoscopic Cholecystectomy in Patients With Acute Cholecystitis
|
||
Withdrawn |
NCT04408872 -
EUS vs EGD in Emergency Room Patients Referred for EGD
|
N/A | |
Recruiting |
NCT02594774 -
Efficacy of Osteopathic Treatment in Function Abdominal Pain in Children and Adolescents
|
N/A |